Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CNAT
  • CUSIP: N/A
  • Web: www.conatuspharma.com
Capitalization:
  • Market Cap: $138.7 million
  • Outstanding Shares: 26,169,000
Average Prices:
  • 50 Day Moving Avg: $6.83
  • 200 Day Moving Avg: $4.60
  • 52 Week Range: $1.45 - $9.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 48.18
  • P/E Growth: -0.18
Sales & Book Value:
  • Annual Revenue: $7.8 million
  • Price / Sales: 17.78
  • Book Value: $0.74 per share
  • Price / Book: 7.16
Profitability:
  • EBIDTA: ($26,140,000.00)
  • Return on Equity: -87.43%
  • Return on Assets: -75.63%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 8.13%
  • Quick Ratio: 8.13%
Misc:
  • Average Volume: 930,687 shs.
  • Beta: 1.34
  • Short Ratio: 3.53
 

Frequently Asked Questions for Conatus Pharmaceuticals (NASDAQ:CNAT)

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.20. The company had revenue of $7 million for the quarter, compared to analyst estimates of $5.88 million. During the same period in the prior year, the company earned ($0.35) EPS. View Conatus Pharmaceuticals' Earnings History.

When will Conatus Pharmaceuticals make its next earnings announcement?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Conatus Pharmaceuticals.

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued 1 year target prices for Conatus Pharmaceuticals' shares. Their predictions range from $7.00 to $26.00. On average, they expect Conatus Pharmaceuticals' share price to reach $14.50 in the next year. View Analyst Ratings for Conatus Pharmaceuticals.

What are analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

  • 1. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
  • 2. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)
  • 3. According to Zacks Investment Research, "Conatus’ progress with the lead candidate, emricasan, has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Given the lack of approved therapies for NASH and the significant market opportunity, its efforts to develop emricasan are promising. Moreover, the lucrative deal signed with Novartis, which will see the companies collaborating for the development and commercialization of emricasan, is a big positive. However, the stock has underperformed the industry so far this year. Emricasan is still several years away from entering the market, if at all. Any development/regulatory setback could hamper Conatus’ prospects. Estimates have come down lately ahead of the Q4 results." (3/14/2017)

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 793,755 shares, a drop of 44.0% from the March 31st total of 1,417,768 shares. Based on an average daily trading volume, of 1,214,842 shares, the short-interest ratio is presently 0.7 days. Currently, 3.7% of the company's shares are short sold.

Who are some of Conatus Pharmaceuticals' key competitors?

Who owns Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.93%), AXA (1.78%), Renaissance Technologies LLC (0.90%), United Capital Financial Advisers LLC (0.59%), Acadian Asset Management LLC (0.57%) and Courage Capital Management LLC (0.48%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Who sold Conatus Pharmaceuticals stock? Who is selling Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AXA. View Insider Buying and Selling for Conatus Pharmaceuticals.

Who bought Conatus Pharmaceuticals stock? Who is buying Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC, Nationwide Fund Advisors, Renaissance Technologies LLC, Morgan Stanley, Courage Capital Management LLC, Geode Capital Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Conatus Pharmaceuticals.

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Conatus Pharmaceuticals stock cost?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $5.30.

Analyst Ratings

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (173.58% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/17/2017HC WainwrightReiterated RatingBuy$18.00MediumView Rating Details
3/16/2017Stifel NicolausReiterated RatingBuy -> Buy$7.00 -> $9.00HighView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
12/23/2016SunTrust Banks, Inc.Reiterated RatingBuy$17.00 -> $26.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyN/AView Rating Details
9/24/2015Piper Jaffray CompaniesReiterated RatingHold$5.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings History by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
2017 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.01)($0.17)
Q2 20173($0.26)$0.00($0.17)
Q3 20172($0.26)($0.01)($0.14)
Q4 20172($0.26)($0.02)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 15.90%
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Conatus Pharmaceuticals (NASDAQ:CNAT)
Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)
Source:
DateHeadline
finance.yahoo.com logoConatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - May 16 at 4:27 PM
seekingalpha.com logoRevisiting Conatus Pharmaceuticals Due To Recent Pipeline Expansion Talks
seekingalpha.com - May 15 at 6:56 PM
americanbankingnews.com logoSunTrust Banks Research Analysts Lower Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT)
www.americanbankingnews.com - May 15 at 9:50 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $7.74 Million
www.americanbankingnews.com - May 13 at 8:00 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics
finance.yahoo.com - May 12 at 4:54 PM
americanbankingnews.com logoZacks: Analysts Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - May 11 at 6:28 PM
finance.yahoo.com logoConatus Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 11 at 4:59 PM
nasdaq.com logoFDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes
www.nasdaq.com - May 11 at 2:38 AM
streetinsider.com logoConatus Pharmaceuticals (CNAT) Plans Offering of Common Stock
www.streetinsider.com - May 11 at 2:38 AM
streetinsider.com logoConatus Pharmaceuticals (CNAT) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - May 10 at 4:36 PM
finance.yahoo.com logoConatus Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 10 at 4:36 PM
finance.yahoo.com logoConatus reports 1Q loss
finance.yahoo.com - May 5 at 9:39 PM
americanbankingnews.com logoConatus Pharmaceuticals' (CNAT) "Buy" Rating Reiterated at Aegis
www.americanbankingnews.com - May 5 at 9:28 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 11:32 PM
finance.yahoo.com logoConatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates
finance.yahoo.com - May 4 at 4:32 PM
benzinga.com logoConatus Announces Exercise of License Option for...
www.benzinga.com - May 4 at 5:55 AM
finance.yahoo.com logoConatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
finance.yahoo.com - May 4 at 5:55 AM
finance.yahoo.com logoNovartis exercises option with Conatus for NASH product
finance.yahoo.com - May 4 at 5:55 AM
nasdaq.com logoWhat's in the Cards for Inovio (INO) This Earnings Season?
www.nasdaq.com - May 3 at 9:23 PM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Impact Conatus Pharmaceuticals (CNAT) Stock Price
www.americanbankingnews.com - May 3 at 2:20 PM
finance.yahoo.com logoCan Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
finance.yahoo.com - May 2 at 7:43 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 2 at 8:04 AM
americanbankingnews.com logoConatus Pharmaceuticals (CNAT) Earns Daily Media Impact Rating of -0.04
www.americanbankingnews.com - April 30 at 10:51 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 29 at 7:32 AM
finance.yahoo.com logoConatus Pharmaceuticals to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 27 at 4:52 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sonus Networks
finance.yahoo.com - April 27 at 11:20 AM
finance.yahoo.com logoConatus (CNAT) Catches Eye: Stock Moves Up 10% in Session
finance.yahoo.com - April 27 at 11:20 AM
americanbankingnews.com logoConatus Pharmaceuticals (CNAT) Receives Daily News Impact Score of -0.10
www.americanbankingnews.com - April 27 at 10:26 AM
finance.yahoo.com logoConatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - April 26 at 5:27 PM
finance.yahoo.com logoConatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 26 at 5:26 PM
streetinsider.com logoConatus Pharmaceuticals (CNAT) Announces Two Posters at ILC on MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients
www.streetinsider.com - April 22 at 9:41 AM
americanbankingnews.com logo Brokerages Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Announce Quarterly Sales of $5.6 Million
www.americanbankingnews.com - April 22 at 7:21 AM
finance.yahoo.com logoConatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis …
finance.yahoo.com - April 21 at 10:23 AM
finance.yahoo.com logoConatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
finance.yahoo.com - April 21 at 10:23 AM
americanbankingnews.com logo-$0.18 Earnings Per Share Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter
www.americanbankingnews.com - April 21 at 12:13 AM
americanbankingnews.com logoPositive Press Coverage Unlikely to Affect Conatus Pharmaceuticals (CNAT) Share Price
www.americanbankingnews.com - April 20 at 6:37 PM
americanbankingnews.com logoConatus Pharmaceuticals (CNAT) Receives Daily Coverage Optimism Score of 0.17
www.americanbankingnews.com - April 16 at 10:17 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Short Interest Update
www.americanbankingnews.com - April 15 at 11:56 AM
americanbankingnews.com logoConatus Pharmaceuticals (CNAT) Earns News Sentiment Score of 0.19
www.americanbankingnews.com - April 13 at 6:34 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Short Interest Down 12.6% in March
www.americanbankingnews.com - April 6 at 1:28 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 10:04 AM
finance.yahoo.com logoConatus to Present at Upcoming Investor Conferences
finance.yahoo.com - March 27 at 12:33 PM
finance.yahoo.com logoCONATUS PHARMACEUTICALS INC. Financials
finance.yahoo.com - March 23 at 4:49 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc Expected to Earn Q1 2017 Earnings of ($0.01) Per Share (CNAT)
www.americanbankingnews.com - March 23 at 9:44 AM
americanbankingnews.com logoFBR & Co Comments on Conatus Pharmaceuticals Inc's FY2019 Earnings (CNAT)
www.americanbankingnews.com - March 22 at 12:25 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Receives "Buy" Rating from Aegis
www.americanbankingnews.com - March 22 at 10:14 AM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - March 22 at 10:13 AM
biz.yahoo.com logoCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 21 at 4:41 PM
biz.yahoo.com logoCONATUS PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:43 PM
americanbankingnews.com logoConatus Pharmaceuticals Inc (CNAT) Price Target Raised to $9.00 at Stifel Nicolaus
www.americanbankingnews.com - March 16 at 12:19 PM

Social

Conatus Pharmaceuticals (CNAT) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff